CYTK News and Press, Cytokinetics Incorporated From 05/22/24

2024-05-22 16:15:13 ET More on Cytokinetics Cytokinetics, Incorporated (CYTK) Q1 2024 Earnings Call Transcript Cytokinetics, Incorporated: Buyout Speculation Persists Cytokinetics: CEO Talks Down Buyout Prospects Cytokinetics CEO Blum says positioned to marke...

Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced t...

SOUTH SAN FRANCISCO, Calif. and NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and Royalty Pharma plc (Nasdaq: RPRX) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten a...

2024-05-17 11:58:33 ET More on Cytokinetics Cytokinetics names Sung Lee as CFO Cytokinetics releases more data on hypertrophic cardiomyopathy drug aficamten Cytokinetics, Incorporated: Buyout Speculation Persists Cytokinetics: CEO Talks Down Buyout Prospects ...

SOUTH SAN FRANCISCO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) announced that the Company will host the muscle biology-focused Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) today, May 17 th , 2024 at the Mission Bay Conference Ce...

SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten at the European Society of Cardiology Congress 2024, taking place in London, UK from August 30, 2024 – September 2, 2024. ...

Analyses of SEQUOIA-HCM Elaborate on Dosing and Measures of Safety During Treatment with Aficamten Results from Cardiopulmonary Exercise Testing Showed Improvement in Exercise Performance were Strongly Correlated to Other Measures of Clinical Improvement Company to Host Investor E...

Statistically Significant and Clinically Meaningful Improvements Observed in Primary Efficacy Endpoint and All Secondary Endpoints; Results Consistent Across All Prespecified Subgroups Rapid and Sustained Improvements Observed in Symptoms and Function; No Treatment Interruptions Due...

2024-05-09 00:06:04 ET Cytokinetics, Incorporated (CYTK) Q1 2024 Earnings Conference Call May 08, 2024, 04:30 PM ET Company Participants Diane Weiser - SVP of Corporate Communication and IR Robert Blum - President and CEO Fady Malik - EVP of R&D Stuart Ku...

2024-05-08 16:00:49 ET More on Cytokinetics Cytokinetics, Incorporated: Buyout Speculation Persists Cytokinetics: CEO Talks Down Buyout Prospects Cytokinetics, Incorporated (CYTK) Q4 2023 Earnings Call Transcript Cytokinetics names Sung Lee as CFO Cyt...